Moderna skyrockets 39% after its early trial of a coronavirus vaccine produced antibodies in all 45 patients (MRNA)

Moderna skyrockets 39% after its early trial of a coronavirus vaccine produced antibodies in all 45 patients (MRNA)

Business Insider

Published

· *Moderna announced on Monday that all 45 patients in an early trial of its coronavirus vaccine candidate produced antibodies that could help protect them against COVID-19.*
· *Shares of the company surged 39%.*
· *The company is aiming to have a vaccine ready for emergency use in the fall.*
· *Watch Moderna trade live on...

Full Article